Latest Breaking News On - Rev gastroenterol - Page 2 : comparemela.com

A Square Peg in a Round Hole: Treating Hepatitis C

The authors propose an investment in patient-centered care strategies to initiate and engage vulnerable populations with curative hepatitis C treatment.

United statesAmelia baileyElizabeth baileyGastroenterol hepatolDepartment of behavioralEngland division of the american liver foundationBrown university school of public healthMainegeneral healthSocial sciencesBrown university schoolPublic healthNew england divisionAmerican liver foundationBoxg sRev gastroenterolSci clin

Serotonin Reuptake Inhibitor and Bleeding Risk, Part 2: Gastrointestinal (GI) Bleeding, Malignancy, Pregnancy, and Surgical Considerations

In this CME article, review literature on SRI-related bleeding complications in patients with GI bleeding, malignancy, perioperative settings, pregnancy, and hormonal therapy.

United statesZuid hollandNew yorkNew south walesVest agderNoord brabantSri lankaGen thorac cardiovascAnesth analgSris ssrisSemin thromb hemostThromb haemostGastroenterol hepatolScandj gastroenterolLos angelesSsris snris

Taiho Oncology Europe GmbH: European Commission Grants Conditional Marketing Authorization for Taiho s LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma

Taiho Oncology Europe GmbH: European Commission Grants Conditional Marketing Authorization for Taiho s LYTGOBI® Tablets for the Treatment of Adults With Cholangiocarcinoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomPeter foertigEurope gmbh zugJunko onishiGastroenterol hepatolHelen morementAtsushi azumaJudy kay mooreEurope gmbUniversity college london hospitalsOncologist at university college london cancer instituteOtsuka holdings co ltdEuropean unionCholangiocarcinoma charityTaiho pharmaceutical co ltdEuropean commission

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results

Al qahirahUnited kingdomHong kongUnited statesAhcene djaballahBen atwell alex shawPanmure gordonEli lillyAnnie chengGastroenterol hepatolZhou yiSara noonanJemma nashMark leeJun saitoStrategic communications

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet - HUTCHMED (China) (NASDAQ:HCM), Takeda Pharmaceutical (NYSE:TAK)

Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) Data support regulatory submissions in the U.S.,

Hong kongUnited kingdomUnited statesAl qahirahSara noonanJemma nashAhcene djaballahJun saitoEli lillyGastroenterol hepatolEuropean medicines agencyJapan pharmaceuticalsEuropean society for medical oncology congressTakeda pharmaceutical company limitedExchange commissionChina national reimbursement drug list